1
|
Wu PY, Chandramohan R, Phan JH, Mahle WT, Gaynor JW, Maher KO, Wang MD. Cardiovascular transcriptomics and epigenomics using next-generation sequencing: challenges, progress, and opportunities. CIRCULATION. CARDIOVASCULAR GENETICS 2014; 7:701-10. [PMID: 25518043 PMCID: PMC4983435 DOI: 10.1161/circgenetics.113.000129] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Po-Yen Wu
- From the School of Electrical and Computer Engineering (P.-Y.W.), School of Biology (R.C.), Georgia Institute of Technology, Atlanta, GA; The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (J.H.P.); The Wallace H. Coulter Department of Biomedical Engineering, School of Electrical and Computer Engineering, Winship Cancer Institute, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory University, Atlanta, GA (M.D.W.); Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (W.T.M., K.O.M.); The Children's Hospital of Philadelphia, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.W.G.)
| | - Raghu Chandramohan
- From the School of Electrical and Computer Engineering (P.-Y.W.), School of Biology (R.C.), Georgia Institute of Technology, Atlanta, GA; The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (J.H.P.); The Wallace H. Coulter Department of Biomedical Engineering, School of Electrical and Computer Engineering, Winship Cancer Institute, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory University, Atlanta, GA (M.D.W.); Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (W.T.M., K.O.M.); The Children's Hospital of Philadelphia, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.W.G.)
| | - John H Phan
- From the School of Electrical and Computer Engineering (P.-Y.W.), School of Biology (R.C.), Georgia Institute of Technology, Atlanta, GA; The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (J.H.P.); The Wallace H. Coulter Department of Biomedical Engineering, School of Electrical and Computer Engineering, Winship Cancer Institute, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory University, Atlanta, GA (M.D.W.); Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (W.T.M., K.O.M.); The Children's Hospital of Philadelphia, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.W.G.)
| | - William T Mahle
- From the School of Electrical and Computer Engineering (P.-Y.W.), School of Biology (R.C.), Georgia Institute of Technology, Atlanta, GA; The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (J.H.P.); The Wallace H. Coulter Department of Biomedical Engineering, School of Electrical and Computer Engineering, Winship Cancer Institute, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory University, Atlanta, GA (M.D.W.); Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (W.T.M., K.O.M.); The Children's Hospital of Philadelphia, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.W.G.)
| | - J William Gaynor
- From the School of Electrical and Computer Engineering (P.-Y.W.), School of Biology (R.C.), Georgia Institute of Technology, Atlanta, GA; The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (J.H.P.); The Wallace H. Coulter Department of Biomedical Engineering, School of Electrical and Computer Engineering, Winship Cancer Institute, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory University, Atlanta, GA (M.D.W.); Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (W.T.M., K.O.M.); The Children's Hospital of Philadelphia, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.W.G.)
| | - Kevin O Maher
- From the School of Electrical and Computer Engineering (P.-Y.W.), School of Biology (R.C.), Georgia Institute of Technology, Atlanta, GA; The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (J.H.P.); The Wallace H. Coulter Department of Biomedical Engineering, School of Electrical and Computer Engineering, Winship Cancer Institute, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory University, Atlanta, GA (M.D.W.); Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (W.T.M., K.O.M.); The Children's Hospital of Philadelphia, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.W.G.)
| | - May D Wang
- From the School of Electrical and Computer Engineering (P.-Y.W.), School of Biology (R.C.), Georgia Institute of Technology, Atlanta, GA; The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (J.H.P.); The Wallace H. Coulter Department of Biomedical Engineering, School of Electrical and Computer Engineering, Winship Cancer Institute, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory University, Atlanta, GA (M.D.W.); Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA (W.T.M., K.O.M.); The Children's Hospital of Philadelphia, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA (J.W.G.).
| |
Collapse
|
4
|
Zhao J, Yang P, Li F, Tao L, Ding H, Rui Y, Cao Z, Zhang W. Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis. PLoS One 2012; 7:e44938. [PMID: 23028693 PMCID: PMC3444501 DOI: 10.1371/journal.pone.0044938] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Accepted: 08/10/2012] [Indexed: 12/04/2022] Open
Abstract
Astragaloside IV (AGS-IV) is a main active ingredient of Astragalus membranaceus Bunge, a medicinal herb used for cardiovascular diseases (CVD). In this work, we investigated the therapeutic mechanisms of AGS-IV at a network level by computer-assisted target identification with the in silico inverse docking program (INVDOCK). Targets included in the analysis covered all signaling pathways thought to be implicated in the therapeutic actions of all CVD drugs approved by US FDA. A total of 39 putative targets were identified. Three of these targets, calcineurin (CN), angiotensin-converting enzyme (ACE), and c-Jun N-terminal kinase (JNK), were experimentally validated at a molecular level. Protective effects of AGS-IV were also compared with the CN inhibitor cyclosporin A (CsA) in cultured cardiomyocytes exposed to adriamycin. Network analysis of protein-protein interactions (PPI) was carried out with reference to the therapeutic profiles of approved CVD drugs. The results suggested that the therapeutic effects of AGS-IV are based upon a combination of blocking calcium influx, vasodilation, anti-thrombosis, anti-oxidation, anti-inflammation and immune regulation.
Collapse
Affiliation(s)
- Jing Zhao
- Department of Natural Medicinal Chemistry, College of Pharmacy, Second Military Medical University, Shanghai, China
- Department of Mathematics, Logistical Engineering University, Chongqing, China
| | - Pengyuan Yang
- Department of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China
| | - Fan Li
- Department of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China
| | - Lin Tao
- Shanghai Center for Bioinformation Technology, Shanghai, China
| | - Hong Ding
- The Teaching Hospital of Chengdu University of TCM, Chengdu, China
| | - Yaocheng Rui
- Department of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China
- * E-mail: (YR); (ZC); (WZ)
| | - Zhiwei Cao
- Shanghai Center for Bioinformation Technology, Shanghai, China
- School of Life Sciences and Technology, Tongji University, Shanghai, China
- * E-mail: (YR); (ZC); (WZ)
| | - Weidong Zhang
- Department of Natural Medicinal Chemistry, College of Pharmacy, Second Military Medical University, Shanghai, China
- * E-mail: (YR); (ZC); (WZ)
| |
Collapse
|
6
|
Christodoulakos G, Lambrinoudaki I, Panoulis C, Papadias C, Economou E, Creatsas G. Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women. Fertil Steril 2004; 82:634-8. [PMID: 15374707 DOI: 10.1016/j.fertnstert.2004.03.030] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2003] [Revised: 03/15/2004] [Accepted: 03/15/2004] [Indexed: 10/26/2022]
Abstract
OBJECTIVE To investigate the effect of continuous combined hormone therapy and raloxifene on serum VE-cadherin. DESIGN The study was double blinded, with a placebo run-in period of 28-50 days. SETTING University menopause clinic. PATIENT(S) Twenty-eight healthy postmenopausal women devoid of climacteric complaints. INTERVENTION(S) Subjects were randomized to 17beta-estradiol (2 mg) + norethisterone acetate (1 mg; E(2)-NETA) or raloxifene hCL (60 mg) for a period of 6 months. MAIN OUTCOME MEASURE(S) Serum VE-cadherin, which was estimated at baseline and at month 6. RESULT(S) Serum VE-cadherin decreased significantly in both E(2)-NETA and raloxifene groups (raloxifene baseline +/- SD: 1.17 +/- 0.44 ng/mL, 6 months: 0.82 +/- 0.29 ng/mL; E(2)-NETA baseline: 1.19 +/- 0.47 ng/mL, 6 months: 0.92 +/- 0.49 ng/mL). Percentage changes from baseline were -21.7 +/- 24.3 for E(2)-NETA and -26.0 +/- 20.6 for raloxifene. CONCLUSION(S) The effect of E(2)-NETA and raloxifene suggests that these drugs may preserve interendothelial junction integrity and control vascular permeability. Although this effect may influence the progress of the atheromatous lesion, its clinical impact on coronary artery disease (CAD) remains uncertain.
Collapse
Affiliation(s)
- George Christodoulakos
- Second Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens, Greece
| | | | | | | | | | | |
Collapse
|